The interesting findings emerging from recent immunotherapeutic agents and strategies appear to be strongly indicative that modulation of a pre-existing, underlying, endogenous immune response is naturally occurring within the patient against their cancer. It is therefore highly likely that both the findings arising from the repeated therapies reported in our present series, and those being reported using current repetitious immunotherapeutic and pathway blockade therapy approaches, appear to cause progressive immunomodulation, perhaps by effectively “synchronising”, “directing”, or “re-focussing” the patient’s in vivo immune response against their cancer.42,43 Better serial blood biomarker analysis and improvement of the accuracy of the timing of therapeutic intervention(s) both appear to be very promising approaches toward obtaining better “synchronization” of therapies with pre-existing in vivo immune responses to thereby improve clinical efficacy.21,22,42–44
Some patients show long-term survival despite advanced melanoma having the reputation of being associated with a particularly dismal prognosis. Clinical course data for 18 cases demonstrates that some patients do defy the odds, in some cases even without therapy, to mount an effective response against their cancer. A combination of selective and combined therapies tailored to the individual patient appears to be capable of modulating the immune response and disease level in a favorable direction for a better outcome. These remarkable cases provide clinical insight into the mechanisms that underpin the better clinical control of metastatic melanoma, and perhaps cancer more generally. Even after failed treatment attempts, long-term patient survival may still be evidenced in a remarkable number of cases in clinical practice. Recent data from the treatment of patients using “pure” immunotherapeutic approaches, such as IL-2, CTLA-4/PD-1 antibody therapies, and repetitive vaccination, would reinforce the notion that restimulation of the immune response in the patient can be remarkably effective in inducing long-term survival.
Although the outlook on metastatic melanoma may seem dismal, cases such as those reported should provide patients with tangible evidence and some hope that their fight against advanced melanoma is not uniformly, nor irrevocably, futile. Physicians, while being realistic, should encourage patients not to become disheartened by failed treatment attempts. Some individuals, even after multiple failed treatment attempts, do ultimately defy their metastatic disease to outlive their initial predicted prognosis, as our findings demonstrate. Continued persistent therapies appear remarkably pivotal. Moreover, newer immunotherapies and new approaches for applying these clinically offer the very tangible prospects of improving the manipulation of endogenous immune responses in patients with advanced cancer.42–44
The authors report no conflicts of interest in this work.
Brendon J Coventry, Dominique Baume, Carrie Lilly
Discipline of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia
1. Hill GL 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A) Cancer. 1984;53(6):1299–1305.
2. Bonnet-Duquennoy M, Papon J, Mishellany F, et al. Promising pre-clinical validation of targeted radionuclide therapy using a [131I] labelled iodoquinoxaline derivative for an effective melanoma treatment J Cancer Sci Ther. 2009;1(1):1–7.
3. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors Cancer. 1997;79(12):2345–2353.
4. Lanitis S, Papaioannou N, Sgourakis G, Seitz A, Zacharakis E, Karaliotas C. Prolonged survival after the surgical management of a solitary malignant melanoma lesion within the pancreas: a case report of curative resection J Gastrointestin Liver Dis. 2010;19(4):453–455.
5. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors Cancer Control. 2005;12(4):223–229.
6. Balch C, Houghton A, Sober A, Soong S Cutaneous Melanoma. 4th ed. St Louis, MO: Quality Medical Publishing, Inc.; 2013.
7. Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: current approaches and future prospects.Cancer Manag Res. 2010;2:197–211.
8. Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma N Engl J Med. 2014;370(7):599–609.
9. Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes J Surg Oncol. 2011;104(2):111–115.
10. Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I) Ann Surg Oncol. 2012; 19(8):2547–2555.
11. Ollila DW, Gleisner AL, Hsueh EC. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma J Surg Oncol. 2011;104(4):420–424.
12. Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma J Am Acad Dermatol. 2009;60(5):872–875.
13. Moncrieff MD, Martin R, O’Brien CJ, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol. 2008;15(11):3022–3027.
14. Atkins MB. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood JK, editor Molecular Diagnosis, Prevention and Therapy of Melanoma. New York, NY: Marcel Dekker; 1997:219–225.
15. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial Lancet Oncol. 2012;13(6):589–597.
16. Giles MH, Coventry BJ. Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit Cancer Manag Res. 2013;5:243–249.
17. Coventry BJ, Kroon HM, Giles MH, et al. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma J Surg Oncol. 2014;109(8):780–785.
18. Menzies AM, Long GV. New combinations and immunotherapies for melanoma: latest evidence and clinical utility Ther Adv Med Oncol. 2013;5(5):278–285.
19. Safa M, Foon K. Cancer vaccines. In: Oldham RK, editor Principles of Cancer Biotherapy. 4th ed. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2013.
20. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin Cancer Res. 2012;18(7):2039–2047.
21. Coventry BJ, Ashdown ML. The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses Cancer Manag Res. 2012;4:215–221.
22. Dutcher JP, Wiernik PH. Deconstructing and reinventing the IL-2 paradigm: can alternate dosing schedules enhance tumor effect Kidney Cancer Journal. 2013;11(1):22–28.
23. Coventry B, Hersey P, Halligan AM, Michele A. Immuno-chemotherapy using repeated vaccine treatment can produce successful clinical responses in advanced metastatic melanoma J Cancer Ther. 2010;1(4):205–213.
24. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med. 2011;364(26):2517–2526.
25. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med. 2011;364(26):2507–2516.
26. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol. 2000;18(1):158–166.